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Pharmaceutical production has to fulﬁll two main requirements
without fail: tomeet the expectations of customers and, on the side
of authorities, production has to meet GMP regulations, which
have the force of law. ‘‘GMP’’ refers to Good Manufacturingaper are those of the authors
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lsevierPractice (see e.g. ICHQ7A, 2000) that requires numerous activ-
ities in order to protect, in turn, the consumer from purchasing a
product that is not effective or – even worse – dangerous. That
means manufacturers and packagers of drugs, veterinary medi-
cines and medical devices need to take proactive steps to ensure
that their products are safe, pure, and effective. GMP regula-
tions require a quality approach to manufacturing, enabling
companies to minimize or eliminate cases of contamination,
mix ups, or any other errors. GMP regulations are often men-
tioned as ‘‘current’’, i.e. ‘‘cGMP’’ expresses that manufacturers
must employ technologies and systems which are up-to-date to
comply with the regulations.
2. Continuous development for better quality
The concept of quality is rather complex, since it includes both
chemical–technological aspects and strategic business consider-
ations. As a consequence of the technical evolution and the com-
petitive economical environment, the pharmaceutical industry
has been going through fundamental transformation in the
recent decade (see e.g. Alt, 2003). These conditions forced phar-
ma producers, for instance, to elaborate customer-oriented
strategies in order to know how to fulﬁll needs and expectancies,
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Faigl, 2007).
The introduction of information technique (IT) in the man-
agement was also advantageous, since computerized systems
can make data collection, handling and archiving easier. Suit-
able software packages are available in the market to obtain
a well-designed basic process for the effective use of manage-
ment resources and to improve the efﬁciency of an enterprise.
The goal is integrating information across the company and
to analyze the whole set of data for shaping a comprehensive
business plan and strategy for the company. Such system is
for, e.g. the well known SAP (System, Application, Product
in Data Processing), and speciﬁcally the quality module of
the software that can be operated in accordance with the cGMP
regulations (Su¨ller-Faigl, 2007). For instance, supplier qualiﬁ-
cation and the whole process of logistics and quality control
of incoming rawmaterial can also be integrated into the system.
Moreover, the producers are expected tomaintain such qual-
ity system that is able to develop itself, i.e. to ‘‘learn’’ from the
recognized mistakes. Therefore different systems were intro-
duced to serve these purposes. As such the well-known CAPA
system (Corrective Action and Preventive Action), under which
the handling of process deviations, out-of-speciﬁcation results,
observations of self-inspections and of external audits (see e.g.
Fields, 2008), etc. can be coordinated. Similarly, the Change
Management System has to ensure that uncontrolled or con-
cealed changes cannot occur in the technology that may affect
the quality of the product.
As it can be seen from the general trends, the development
of technical-informational background of pharma companies
and the expectancies of customers and/or authorities are in
interaction with each other: while tools become more effective
and sophisticated, the company requirements are also harder
and very often the approach of a given process also becomes
more complex. The publication of the new FDA guidance
(FDA, 2011) ﬁts into this progress.3. New aspects of validation activities
According to the corresponding ICH (International Confer-
ence on Harmonization) guide (see ICH Q7, 2000, 12.40)
‘‘process validation (PV) is the documented evidence that the
process, operated within established parameters, can perform
effectively and reproducibly to produce an intermediate or
API meeting its predetermined speciﬁcations and quality attri-
butes’’. However, in 2011 the FDA guidance states that
‘‘process validation is deﬁned as the collection and evaluation
of data, from the process design stage through commercial
production, which establishes scientiﬁc evidence that a process
is capable of consistently delivering quality product’’. In the
new context the PV activities are divided into three stages:
Stage 1: Process design: that means the collection of data and
gaining knowledge during development and scaling
up experiments.
Stage 2: Process qualiﬁcation: evaluation and conﬁrmation of
the designed process, establishing of scientiﬁc evidence
that the process is reproducible, ‘‘quality bothwithin a
batch and between batches’’ (FDA, 2011) is assured.
Actually, the activities of this stage are almost equiva-
lent with the earlier PV activities (see also Pluta, 2011).Stage 3: Continued process veriﬁcation: it is the assurance of that
the production process remains in the state of control
during the entire period of the routine production.
That means, while in 1987 the FDA emphasized the valida-
tion protocol, testing, the results and the corresponding docu-
mentation; according to the 2011 lifecycle approach, the
validation activities start immediately in the development stage
and continue throughout the whole commercial life of the
product (see also Pluta, 2011). In practice, the number of pro-
cesses run depends on the complexity of the process, etc. The
expectation of ICH Q7 (ICH Q7, 2000) is similar: ‘‘For pro-
spective and concurrent validations, three consecutive success-
ful production batches should be used as a guide, but there
may be situations where additional process runs are warranted
to prove consistency of the process (e.g. complex API pro-
cesses or API processes with prolonged completion times).’’
After declaring the process validated in the PV report, the val-
idation activity is ﬁnished according to the ‘‘old’’ concept.
It was also stated in 1987 by the FDA: ‘‘This guideline is
issued under Section 10.90 (21 CFR 10.90) and is applicable
to the manufacture of pharmaceuticals and medical devices.
It states principles and practices of general applicability that
are not legal requirements but are acceptable to the FDA.’’
That means actually, that the previous guideline did not dis-
cuss PV of API production itself, only the PV of ﬁnal products
and medical devices was discussed.
In the light of the 2011 guide: quality cannot be adequately,
or merely assured by in-process and ﬁnished-product inspection
or testing. The development of the process and of the product,
the demonstration of process conformity and the maintenance
of the validated, controlled state of the production are inte-
grated into a single complex aspect. Ultimately, it is expected
from the producer that each step of a manufacturing process
has to be controlled to consistently assure that the ﬁnished prod-
uct meets all quality attributes included in the speciﬁcations.
It has to be noted that this concept is not really new to the
USA either as it was pointed out by Pluta (2011) (see also Evans,
2000). It is also in line with the ICH recommendation for build-
ing up suitable PV program (ICH Q7, 2000, 12.5) that requires
periodical evaluation to verify that the process still operates in
a valid manner (see also Hiyama, 2011). Moreover ICH Q11,
Step 3 (2011) has allowed: ‘‘As an alternative to the traditional
process validation, the continuous process veriﬁcation can be
utilized in process validation protocols for the initial commer-
cial production and for manufacturing process changes for the
continual improvement throughout the remainder of the prod-
uct lifecycle’’ However, the coherence of life stages of a product
became emphasized in 2011 by FDA.4. The role of development as a part of the validation activities
Already in 2003, the ICH issued ‘‘A New Vision for Ensuring
Product Quality’’ that addressed a ‘‘harmonized pharmaceuti-
cal quality system applicable across the life cycle of the product
emphasizing an integrated approach to quality risk manage-
ment and science’’ (see e.g. Hiyama, 2011; ICH Q8, 2009;
ICH Q9, 2005; ICH Q10, 2008). In this approach also the
(transferred) knowledge forms the basis for the manufacturing
process, control strategy, PV approach and ongoing continual
improvement. (ICH Q10, 2008 3.1.2).
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stood that Stage 1 is generally described as ‘‘process under-
standing’’. Every following activity is based on the
information collected in the development stage.
A fundamental step before PV is to recognize the critical
steps and parameters of the production process that inﬂuence
product quality. It is because manufacturers have to under-
stand and detect occurring variations. The sources, presence
and degree, impact of variations should be identiﬁed, and suit-
able control has to be established. The early process design
does not have to be conducted under cGMP, but decision
and justiﬁcation of controls are made in form of reviewed
documents.
In practice, critical parameters have to be established based
on true scientiﬁc justiﬁcation through the course of quality risk
analysis. The role of R&D is to deliver data for risk analysis in
the form of detailed development reports. Thus, risk assess-
ment conducted prior to initial commercial validation batches
can highlight the areas where particular focus and data are
needed to demonstrate the desired high level of assurance of
commercial process robustness (see e.g. Hiyama, 2011; Pluta,
2011). For reliable work in this stage, the collaboration be-
tween R&D and manufacturing function is crucial. As Hiyama
(and many other authors) pointed out, ‘‘for innovative PV ap-
proaches, technology development and senior management
support are required’’ (Hiyama, 2011).
The new FDA guide issued in 2011 states that ‘‘the terms
attributes (e.g. quality, product, component) and parameters
(e.g. process, operating, equipment) are not categorized with
respect to criticality’’. The reason for this statement is ex-
plained by the next sentence ‘‘the perception of criticality as
a continuum rather than a binary state is more useful’’, since
risk based decisions are expected throughout the lifecycle of
PV. All attributes and parameters should be evaluated in terms
of their roles in the process and impact on the product or in-
process material, and reevaluated every time when new infor-
mation becomes available. It is also important to keep in mind
that the degree of control over attributes or parameters should
be commensurate with their risk to the process and process
output, i.e. for attributes or parameters posing higher risk,
higher degree of control is appropriate. The ﬁnal goal of PV
is still homogeneity within a batch and consistency between
batches.
5. Conclusions
The changing attitude of regulations and authorities often re-
quires the re-establishment of the strategy of quality manage-
ment and, in line with this fact, even the re-thinking of theorganization structure of quality assurance or allocation of hu-
man resources may be necessary. The quality has to be built
into the product already from the stage of design thus the
importance of archived documents (i.e. development reports)
from the stage of development, even in case of old, known
and well-managed technologies became pronounced. Develop-
ment experiences have to be properly documented and handled
as an extremely important source of knowledge in solving fur-
ther technological problems since it creates the scientiﬁc justi-
ﬁcation and knowledge source of every further activity in and
for production.
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